TPST — Tempest Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Tempest To Report Early Results From Global Randomized Phase 1B/2 Combination Study Of Tpst-1120 In First-Line Hepatocellular Carcinoma
Tempest Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
U.S. RESEARCH ROUNDUP- Acuity Brands, Hershey, Phreesia
Brief: Tempest Expects To Have Sufficient Resources To Fund Operations Through Q2 Of 2024
Brief: Tempest Presents Data Showing Tpst-1120-Induced Pharmacodynamic Changes Consistent With Clinical Benefit Observed In Patients With Cancer
Tempest Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Tempest Reports Q3 Financial Results, Provides Business Update
Tempest Therapeutics Inc expected to post a loss of 80 cents a share - Earnings Preview
Brief: Tempest Therapeutics reports Q2 results
Tempest Therapeutics Inc expected to post a loss of 92 cents a share - Earnings Preview
Brief: Tempest Provides Asco Kol Feedback On Tpst-1120 Clinical Results And Updated Financial Guidance
Pains and gains for cancer drugmakers ahead of industry meet
Brief: Tempest Reports Positive Tpst-1120 Clinical Data From Phase 1 Trial In Patients With Advanced Solid Tumors At 2022 Asco Annual Meeting
Brief: Tempest Therapeutics Files Prospectus Related To Proposed Resale Of Up To 6,355,932 Shares
Brief: Rock Springs Capital Management LP Reports 11.48% Passive Stake In Tempest Therapeutics Inc As Of Dec. 22
Brief: Tempest Announces First Patient Dosed With TPST-1495 In Combination With Pembrolizumab
Tempest Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Tempest Announces First Patient Dosed In Randomized Study Evaluating TPST-1120
Tempest Therapeutics Inc reports results for the quarter ended in June - Earnings Summary